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to identify individuals for hepatitis C treatment are overly restrictive and may inappropriately exclude individuals who may benefit from hepatitis C therapy. This is important not only for Federal prisoners, but also for many state and local correctional facilities because they follow The Federal Bureau of Prisons protocols. Given that most facilities do not treat without a biopsy, these protocols should be changed to allow a liver biopsy for anyone with active hepatitis C, especially those with any abnormality in their hepatic enzymes. This would go a long way toward bringing correctional medical standards regarding hepatitis C in alignment with current community standards of care and treatment.
